- Home
- NMM vs OCS Comparison
NMM vs OCS Comparison
Compare NMM & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMM
- OCS
- Stock Information
- Founded
- NMM 2007
- OCS 2003
- Country
- NMM Greece
- OCS Switzerland
- Employees
- NMM N/A
- OCS N/A
- Industry
- NMM Marine Transportation
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- NMM Consumer Discretionary
- OCS Health Care
- Exchange
- NMM Nasdaq
- OCS Nasdaq
- Market Cap
- NMM 1.1B
- OCS 1.0B
- IPO Year
- NMM 2007
- OCS N/A
- Fundamental
- Price
- NMM $38.63
- OCS $19.00
- Analyst Decision
- NMM Strong Buy
- OCS Strong Buy
- Analyst Count
- NMM 1
- OCS 3
- Target Price
- NMM $80.00
- OCS $35.33
- AVG Volume (30 Days)
- NMM 99.9K
- OCS 27.1K
- Earning Date
- NMM 08-19-2025
- OCS 08-26-2025
- Dividend Yield
- NMM 0.52%
- OCS N/A
- EPS Growth
- NMM N/A
- OCS N/A
- EPS
- NMM 11.16
- OCS N/A
- Revenue
- NMM $1,319,623,000.00
- OCS $847,333.00
- Revenue This Year
- NMM N/A
- OCS $18.70
- Revenue Next Year
- NMM $7.93
- OCS $1,059.78
- P/E Ratio
- NMM $3.46
- OCS N/A
- Revenue Growth
- NMM 0.28
- OCS N/A
- 52 Week Low
- NMM $28.37
- OCS $10.79
- 52 Week High
- NMM $65.89
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- NMM 48.79
- OCS 46.89
- Support Level
- NMM $36.62
- OCS $18.87
- Resistance Level
- NMM $39.41
- OCS $19.75
- Average True Range (ATR)
- NMM 1.18
- OCS 0.43
- MACD
- NMM -0.24
- OCS -0.11
- Stochastic Oscillator
- NMM 32.28
- OCS 32.43
About NMM Navios Maritime Partners LP Common Units Representing Limited Partner Interests
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.